Category Archives: Health Care

What are the key trends in global mHealth industry and which of its segments will be the key growth drivers over the next 12 months?

  1. Monitoring services (up to 66% of the Global mHealth market share)
  • Remote Patient monitoring
      • (e.g. Obesity Management
      • Healthy Living
      • Pregnancy Tips
      • Elderly Care
      • Smoking De-addiction
      • Infectious Diseases
      • Reproductive Health
      • Child Health / Child Care…)
  • Video conferencing and online consultations
          • e.g. Telephone-based consultations
          • Video consultations
          • Text-based consultations…
  • Personal healthcare devices
  • Wireless access to patient records and prescriptions
  • Chronic disease managementIndependent ageing applications in developed markets 
  • Post acute care monitoring services
  • Monitoring of patients with metabolic conditions such as obesity and Diabetes (is expected to comprise about 40% of the chronic disease management Segment)
  • Monitoring patients with cardiovascular conditions such as hypertension, coronary artery disease and congestive heart failure (is expected to contribute about 45% to chronic disease management revenues in the US and about 80% in China).
  • Analysis of general health and wellness data gathered by mobile devices

 2. Diagnostic Services (up to 16% of the Global mHealth market share)

  • Interactive messages that help patients self-diagnose minor ailments
  • Medical call centres / help-lines manned by healthcare professionals
  • Telemedicine solutions that enable doctors to ‘see’ patients through wireless broadband
  • A majority of the revenues from Diagnosis services are expected to come from call-centre and mobile telemedicine solutions.              
  • The adoption of Diagnosis services is expected to support developing markets in bridging their healthcare access challenges.

 3. Treatment Services (up to 11% of the Global mHealth market share)

  • Emergency Response
  • Ambulance based Solutions
  • Treatment Compliance
  • Appointment Reminders
  • Use of mobile device to explain/demonstrate during office visits
  • Provide patients access to portions of their medical record
  • Drug adherence and other health-related communication

 4. Healthcare System strengthening Services (up to 7% of the Global mHealth market share)

  • Patient-centred care
  • Wellness (up to 3% of the Global mHealth market share)
  • Prevention (up to 1% of the Global mHealth market share)
      • e.g. Drug Abuse Prevention
  • Information Lookup and Decision Support
  • Health Surveys & Healthcare Surveillance
  • Healthcare Practitioner Support
  • Healthcare Administration& administrative communication

Roche Seeks Sequencing Strategy

Roche’s failed 2012 attempt to acquire Illumina for $6.7 billion has not stopped the global leader in clinical diagnostics from its intent to be a player in the high growth “nex-gen” sequencing market. Several recent moves by this diagnostics leader provide insight into Roche’s sequencing strategy. Continue reading

Clinical Labs Cut Costs but Face Future Challenges

Taking a play from many healthcare payer playbooks, hospital labs have instituted cost cutting and proactive screening programs that yield substantial bottom line benefits. Copying third party payer pre-certification programs for high-cost tests, a Florida healthcare system initiated an esoteric test approval program for any request in excess of $1,000. The result of this program was an annual savings of $220,000. The lab then went on to introduce and monitor test formularies designed to reduce the volume of send out tests to commercial labs. This saved $74,000 and utilizing “best practices” for blood products added another $412,000 in savings. Continue reading

Vermillion and Quest Diagnostics Part Ways

Vermillion has long its OVA1 In Vitro Diagnostic Multi-Variant Index Assay (IVDMIA) for ovarian cancer. OVA1 is one of a handful of FDA approved IVDMIAs and was predicted to have a much greater market presence than actually occurred, despite its partnership with Quest Diagnostics, the largest commercial reference lab in the US. Now, Vermillion announced that the company has terminated its licensing agreement with Quest for OVA1 and Vasclir diagnostic tests. Continue reading

Trends in Physician Office Practices

Hospitals continue to increase their acquisition of physician practices. According to AHA statistics, hospitals employ over 212,000 doctors and this number is expected to increase as both hospitals and doctors seek mutually beneficial alignments. Currently, just over 55% of physicians remain independent. A recent survey revealed that 32% of first year residents prefer hospital employment and the HealthLeaders Media report found that 70% of US hospitals intend to employ more physicians in the next three years. Continue reading

Hospital Acquired Infection Space Sees New Entrant

The Hospital Acquired Infection (HAI) space is growing both in size and new competitors. Abacus Diagnostica just announced the results of a new study demonstrating comparable sensitivity and specificity to the gold standard of culture-based testing and Cepheid’s GeneXpert C. difficile test. In addition to Cepheid, there are numerous other competitors in the HAI segment including BD, Quidel, Meridian, Nanosphere and other companies have C. difficile and Methicillin Resistant Staph Aureus (MRSA) tests under development. Continue reading

FDA Sets Sights on Laboratory Developed Tests

According to leading experts, there are over 3,000 Laboratory Developed Tests (LDTs) marketed in the US. LDTs are tests developed by large, medium, small and specialized clinical labs such as Quest Diagnostics, LabCorp, Myriad Genetics, Genomic Health, Sequenom and many others. LDTs play an import role in health care, especially in delivering molecular diagnostic and genetic screening results and interpretation to clinicians. To date, there is no single registry source to track existing LDTs and they continue to grow as labs deploy these high cost and high margin tests as rapid go-to-market strategies, since they do not require lengthy clinical trials and FDA approval. Now, the FDA has announced its intent to regulate LDTs. Continue reading

Commercial Reference Labs Face Headwinds

Commercial Reference Labs (CRLs) play an essential role in the delivery of heathcare. The largest companies in this segment are two well-known competitors Quest Diagnostics (NYSE: DGX) and LabCorp (NYSE: LH). Also competing in the reference lab market are smaller companies such as Bio-Reference Laboratories (BRLI), ARUP Laboratories and specialty companies with different go to market business models such as Myriad Genetics (NASDAQ: MYGN) and Genomic Health (NASDAQ: GHDX). Rounding out the market are100-250 small labs that focus on providing testing services to nursing homes and other alternate site care facilities and hospital labs that have their own outreach testing programs. Clinical lab test results account for over 70% of all clinical decisions according to leading industry experts, which highlights the importance of these companies in the healthcare continuum. Continue reading

Prostate Market Expected to Expand as New Entrants Drive Growth

There are approximately 240,000 men diagnosed with prostate cancer in the US each year and 30,000 will die from the disease. According to the National Institutes of Health, prostate cancer costs associated with prostate cancer were $12 billion in 2010.

In order to attempt to diagnose prostate cancer as early as possible, 23 million men are tested for the Prostate Specific Antigen (PSA) each year and 1 million have prostate biopsies for analysis by pathologists to determine if the biopsy is benign or cancerous. Continue reading